Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, February 26th.

Minerva Neurosciences Stock Down 11.0 %

Minerva Neurosciences stock opened at $1.37 on Thursday. The business’s 50-day moving average price is $1.87 and its 200 day moving average price is $2.19. The firm has a market cap of $9.58 million, a price-to-earnings ratio of -3.11 and a beta of 0.10. Minerva Neurosciences has a 52 week low of $1.26 and a 52 week high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.49. Equities analysts expect that Minerva Neurosciences will post -0.3 EPS for the current year.

Hedge Funds Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC increased its holdings in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,764 shares of the biopharmaceutical company’s stock after buying an additional 8,525 shares during the period. Citadel Advisors LLC owned about 0.37% of Minerva Neurosciences worth $57,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 34.56% of the stock is owned by hedge funds and other institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.